Alembic Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St

June 26, 2024

Alembic Pharmaceuticals (NSE:APLLTD) Full Year 2024 Results

Key Financial Results

Revenue: ₹62.3b (up 10% from FY 2023).
Net income: ₹6.16b (up 80% from FY 2023).
Profit margin: 9.9% (up from 6.1% in FY 2023). The increase in margin was driven by higher revenue.
EPS: ₹31.33 (up from ₹17.40 in FY 2023).

APLLTD Post-Clinical Trial Products

Pre-registration: 90.
Approved (during full year): 15.
Launched (during full year): 41.

revenue-and-expenses-breakdown — NSEI:APLLTD Revenue and Expenses Breakdown June 26th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Alembic Pharmaceuticals EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) exceeded analyst estimates by 3.7%.

The primary driver behind last 12 months revenue was the Outside India segment contributing a total revenue of ₹37.4b (60% of total revenue). Explore how APLLTD's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Pharmaceuticals industry in India.

Performance of the Indian Pharmaceuticals industry.

The company's shares are up 4.6% from a week ago.

Risk Analysis

It is worth noting though that we have found 1 warning sign for Alembic Pharmaceuticals that you need to take into consideration.

Valuation is complex, but we're helping make it simple.

Find out whether Alembic Pharmaceuticals is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.